Announcements Trials

Browse Landscape

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1 Solid Tumor 1 Prostatic Neoplasms, Castration-Resistant 1 Pancreatic Neoplasms 1 Colorectal Neoplasms 1 Breast Neoplasms 1

Interventions

Cetuximab 44 Oxaliplatin 39 Irinotecan 38 Fluorouracil 36 Capecitabine 36 Bevacizumab 36 pembrolizumab 35 Leucovorin 34 Nivolumab 21 Gemcitabine 17 regorafenib 13 Panitumumab 12 IFL protocol 12 Folfox protocol 12 Cyclophosphamide 12 Pemetrexed 11 Cisplatin 11 tislelizumab 9 Paclitaxel 9 HMPL-013 9 Carboplatin 9 130-nm albumin-bound paclitaxel 8 durvalumab 7 Specimen Handling 7 Docetaxel 7 trametinib 6 Trifluridine 6 Ipilimumab 6 Drug Therapy 6 trifluridine tipiracil drug combination 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Colorectal Neoplasms × zimberelimab × Clear all

NCT04660812 2025-10-20

ARC-9

Arcus Biosciences, Inc.

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡